Spotlight on JLABS

Sep 27 2016

Come one, come all! You are invited to learn more about some of the exciting companies creating scientific breakthroughs at JLABS in Toronto. JLABS @ Toronto officially opened in May with 22 companies and has several more in the pipeline. Four companies will give candid, informative presentations detailing their executive teams, an overview of their company and highlighting their reasons for joining JLABS. Don't miss this opportunity to learn more about the progress of this exciting project and meet the companies within JLABS. Please note that the presentations at this event will include publicly available, non-confidential information only.

Tuesday September 27th, 2016

11:30am | Lunch
12:00pm | Presentations
1:00pm | Program Close

Presenting Companies:
AvroBio read more»
Nanovista read more»
Neutun Labs read more»
Realist Pharma read more»

Please RSVP online so that we can get an accurate headcount for food and beverages. We will not be accepting walk-ups once the event is sold out.

JLABS @ Toronto
661 University Ave, Suite 1300
Toronto, Ontario

Presenting Companies' Descriptions:

AVROBIO is a clinical stage company developing transformative ex-vivo gene therapies targeting cancer and rare diseases. The catalyst for creating AVROBIO is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to treat serious debilitating disease resulting in durable patient outcomes. A unifying theme across our portfolio is the expert design and manufacturing of optimal cell and gene delivery systems. AVROBIO has offices in both Toronto, ON and Cambridge, MA.

Nanovista offers an innovative solution that enables surgeons to perform high-precision cancer surgery. A surgeon’s job is becoming more challenging due to advances in cancer diagnosis and screening. In fact, they are required to resect increasingly small tumors that are often invisible and not palpable, while preserving as much of the surrounding healthy tissue as possible in order to minimize size effects for patients. Our lead product is a multimodal nano-sized imaging agent with the capability of allowing surgeons to better visualize and locate tumors, their boundaries, as well as any malignant lymph nodes, both pre-operatively using CT imaging for improved surgical planning, as well as intra-operatively using fluorescence imaging for more accurate resection. Our team is composed of 3 translational scientists supported by world renowned cancer surgeons who have been helping us assess the clinical benefits of our agent in relevant animal models of human cancer. To date, we have obtained very promising data in 10 different solid tumor models suggesting that our technology has great potential to bring about broad therapeutic benefits to millions of patients affected with cancer. We also hold a strong IP position with a number of patents issued and pending.

Realist Pharma
Realist Pharma is an immunotherapeutics company whose programs are underpinned by its discovery that carbohydrates in >10 well-known & widespread tumor marker gangliosides (TMGs) have well-defined and highly conserved structures which, for the first time, Realist has successfully targeted using active immune responses. Realist's two core programs are focused on oncology: REAL-1 (autologous cell therapies with no genetic engineering) and REAL-2 (vaccination using NCE glycomimetics).